4-Hydroxyderricin from Angelica keiskei promotes the stability of BRCA1 in triple-negative breast cancer cells through inhibition of cathepsin S | Synapse
March 3, 2026
4-Hydroxyderricin from Angelica keiskei promotes the stability of BRCA1 in triple-negative breast cancer cells through inhibition of cathepsin S
Key Points
4-hydroxyderricin promotes the stability of BRCA1, benefiting cancer treatment.
Results indicate a significant 40% increase in BRCA1 stability when cathepsin S is inhibited.
Analysis of treatment effects shows a molecular interaction with cathepsin S in cancer cells.
These findings highlight the potential of 4-hydroxyderricin as a novel therapy for triple-negative breast cancer.